Bionano Genomics Inc
BNGO1.600USD
+0.010+0.63%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
15.57MMarket Cap
LossP/E TTM
More Details of Bionano Genomics Inc Company
Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Bionano Genomics Inc Info
Ticker SymbolBNGO
Company nameBionano Genomics Inc
IPO dateAug 01, 2018
CEOHolmlin (R. Erik)
Number of employees98
Security typeOrdinary Share
Fiscal year-endAug 01
Address9540 Towne Centre Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18588887600
Websitehttps://bionano.com/
Ticker SymbolBNGO
IPO dateAug 01, 2018
CEOHolmlin (R. Erik)
Company Executives of Bionano Genomics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Oldakowski
Mr. Mark Oldakowski
Chief Operating Officer
Chief Operating Officer
382.00
-13.38%
Mr. Mark Adamchak
Mr. Mark Adamchak
Vice President - Accounting, Principal Accounting Officer
Vice President - Accounting, Principal Accounting Officer
264.00
-2.58%
Ms. Hannah Mamuszka
Ms. Hannah Mamuszka
Independent Director
Independent Director
109.00
-0.91%
Dr. David L. Barker, Ph.D.
Dr. David L. Barker, Ph.D.
Independent Director
Independent Director
97.00
--
Mr. Christopher J. Twomey, CPA
Mr. Christopher J. Twomey, CPA
Independent Director
Independent Director
17.00
-84.26%
Dr. R. Erik Holmlin, Ph.D.
Dr. R. Erik Holmlin, Ph.D.
President, Chief Executive Officer, Principal Financial Officer, Director
President, Chief Executive Officer, Principal Financial Officer, Director
--
--
Mr. David Holmes
Mr. David Holmes
Investor Relations Officer
Investor Relations Officer
--
--
Dr. Yvonne Linney, Ph.D.
Dr. Yvonne Linney, Ph.D.
Independent Director
Independent Director
--
--
Dr. Aleksandar Rajkovic, M.D., Ph.D.
Dr. Aleksandar Rajkovic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Albert A. Luderer, Ph.D.
Dr. Albert A. Luderer, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Oldakowski
Mr. Mark Oldakowski
Chief Operating Officer
Chief Operating Officer
382.00
-13.38%
Mr. Mark Adamchak
Mr. Mark Adamchak
Vice President - Accounting, Principal Accounting Officer
Vice President - Accounting, Principal Accounting Officer
264.00
-2.58%
Ms. Hannah Mamuszka
Ms. Hannah Mamuszka
Independent Director
Independent Director
109.00
-0.91%
Dr. David L. Barker, Ph.D.
Dr. David L. Barker, Ph.D.
Independent Director
Independent Director
97.00
--
Mr. Christopher J. Twomey, CPA
Mr. Christopher J. Twomey, CPA
Independent Director
Independent Director
17.00
-84.26%
Dr. R. Erik Holmlin, Ph.D.
Dr. R. Erik Holmlin, Ph.D.
President, Chief Executive Officer, Principal Financial Officer, Director
President, Chief Executive Officer, Principal Financial Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.28M
48.66%
Software
1.64M
24.28%
Instruments
1.40M
20.78%
Services and other
423.00K
6.28%
By RegionUSD
Name
Revenue
Proportion
EMEIA
3.23M
47.94%
Americas
2.93M
43.46%
Asia Pacific
579.00K
8.60%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.28M
48.66%
Software
1.64M
24.28%
Instruments
1.40M
20.78%
Services and other
423.00K
6.28%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
5.16%
Heights Capital Management, Inc.
4.67%
Abbe (Richard)
3.17%
Iroquois Capital Management, LLC
1.91%
UBS Financial Services, Inc.
0.62%
Other
84.47%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
5.16%
Heights Capital Management, Inc.
4.67%
Abbe (Richard)
3.17%
Iroquois Capital Management, LLC
1.91%
UBS Financial Services, Inc.
0.62%
Other
84.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.44%
Corporation
5.16%
Individual Investor
3.19%
Hedge Fund
2.07%
Investment Advisor/Hedge Fund
0.37%
Research Firm
0.10%
Other
82.67%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
123
914.11K
2.31%
--
2025Q3
133
914.11K
2.58%
+813.59K
2025Q2
185
100.52K
13.17%
-3.70K
2025Q1
250
104.22K
14.32%
-326.48K
2024Q4
274
101.50K
13.43%
+9.88K
2024Q3
289
91.66K
15.30%
-74.07K
2024Q2
302
110.36K
23.52%
-110.43K
2024Q1
309
82.51K
16.21%
-65.29K
2023Q4
315
103.94K
16.84%
+13.56K
2023Q3
336
90.39K
20.40%
+284.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
525.00K
5.42%
+525.00K
--
Sep 17, 2025
Heights Capital Management, Inc.
475.00K
4.91%
+475.00K
--
Sep 16, 2025
Abbe (Richard)
157.50K
1.63%
+157.50K
--
Sep 16, 2025
Iroquois Capital Management, LLC
367.50K
3.8%
+367.50K
--
Sep 16, 2025
UBS Financial Services, Inc.
2.31K
0.02%
+397.00
+20.79%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.87K
0.19%
+3.37K
+21.70%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Aug 04, 2023
Merger
10→1
Aug 04, 2023
Merger
10→1
Date
Type
Ratio
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Jan 22, 2025
Merger
60→1
Aug 04, 2023
Merger
10→1
Aug 04, 2023
Merger
10→1
Aug 04, 2023
Merger
10→1
Aug 04, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Bionano Genomics Inc?
The top five shareholders of Bionano Genomics Inc are:
Lincoln Alternative Strategies LLC holds 525.00K shares, accounting for 5.42% of the total shares.
Heights Capital Management, Inc. holds 475.00K shares, accounting for 4.91% of the total shares.
Abbe (Richard) holds 157.50K shares, accounting for 1.63% of the total shares.
Iroquois Capital Management, LLC holds 367.50K shares, accounting for 3.80% of the total shares.
UBS Financial Services, Inc. holds 2.31K shares, accounting for 0.02% of the total shares.
Lincoln Alternative Strategies LLC holds 525.00K shares, accounting for 5.42% of the total shares.
Heights Capital Management, Inc. holds 475.00K shares, accounting for 4.91% of the total shares.
Abbe (Richard) holds 157.50K shares, accounting for 1.63% of the total shares.
Iroquois Capital Management, LLC holds 367.50K shares, accounting for 3.80% of the total shares.
UBS Financial Services, Inc. holds 2.31K shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Bionano Genomics Inc?
The top three shareholder types of Bionano Genomics Inc are:
Lincoln Alternative Strategies LLC
Heights Capital Management, Inc.
Abbe (Richard)
Lincoln Alternative Strategies LLC
Heights Capital Management, Inc.
Abbe (Richard)
How many institutions hold shares of Bionano Genomics Inc (BNGO)?
As of 2025Q4, 123 institutions hold shares of Bionano Genomics Inc, with a combined market value of approximately 914.11K, accounting for 2.31% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.26%.
What is the biggest source of revenue for Bionano Genomics Inc?
In FY2025Q2, the Consumables business generated the highest revenue for Bionano Genomics Inc, amounting to 3.28M and accounting for 48.66% of total revenue.
